nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—PGR—ovarian cancer	0.369	0.613	CbGaD
Levonorgestrel—ESR1—ovarian cancer	0.233	0.387	CbGaD
Levonorgestrel—CYP19A1—Paclitaxel—ovarian cancer	0.0653	0.581	CbGbCtD
Levonorgestrel—CYP3A4—Topotecan—ovarian cancer	0.0167	0.149	CbGbCtD
Levonorgestrel—CYP19A1—follicular fluid—ovarian cancer	0.0152	0.153	CbGeAlD
Levonorgestrel—CYP3A4—Vinorelbine—ovarian cancer	0.0118	0.105	CbGbCtD
Levonorgestrel—PGR—corpus luteum—ovarian cancer	0.00974	0.0979	CbGeAlD
Levonorgestrel—CYP19A1—corpus luteum—ovarian cancer	0.00877	0.0881	CbGeAlD
Levonorgestrel—CYP3A4—Paclitaxel—ovarian cancer	0.00828	0.0735	CbGbCtD
Levonorgestrel—PGR—ovarian follicle—ovarian cancer	0.00762	0.0766	CbGeAlD
Levonorgestrel—CYP19A1—ovarian follicle—ovarian cancer	0.00686	0.0689	CbGeAlD
Levonorgestrel—CYP3A4—Docetaxel—ovarian cancer	0.00598	0.0532	CbGbCtD
Levonorgestrel—ESR1—ovarian follicle—ovarian cancer	0.00596	0.0599	CbGeAlD
Levonorgestrel—CYP3A4—Doxorubicin—ovarian cancer	0.00446	0.0396	CbGbCtD
Levonorgestrel—PGR—oviduct—ovarian cancer	0.00335	0.0336	CbGeAlD
Levonorgestrel—AR—oviduct—ovarian cancer	0.00267	0.0268	CbGeAlD
Levonorgestrel—ESR1—oviduct—ovarian cancer	0.00262	0.0263	CbGeAlD
Levonorgestrel—SRD5A1—gonad—ovarian cancer	0.00213	0.0214	CbGeAlD
Levonorgestrel—SRD5A1—female reproductive system—ovarian cancer	0.0019	0.0191	CbGeAlD
Levonorgestrel—SRD5A1—testis—ovarian cancer	0.00154	0.0154	CbGeAlD
Levonorgestrel—PGR—myometrium—ovarian cancer	0.00107	0.0108	CbGeAlD
Levonorgestrel—AR—myometrium—ovarian cancer	0.000853	0.00857	CbGeAlD
Levonorgestrel—PGR—epithelium—ovarian cancer	0.000841	0.00845	CbGeAlD
Levonorgestrel—ESR1—myometrium—ovarian cancer	0.000838	0.00842	CbGeAlD
Levonorgestrel—SHBG—endometrium—ovarian cancer	0.000837	0.00841	CbGeAlD
Levonorgestrel—PGR—uterine cervix—ovarian cancer	0.000833	0.00838	CbGeAlD
Levonorgestrel—ESR1—embryo—ovarian cancer	0.000806	0.0081	CbGeAlD
Levonorgestrel—PGR—decidua—ovarian cancer	0.000794	0.00798	CbGeAlD
Levonorgestrel—SHBG—gonad—ovarian cancer	0.000776	0.0078	CbGeAlD
Levonorgestrel—SHBG—uterus—ovarian cancer	0.000771	0.00775	CbGeAlD
Levonorgestrel—PGR—endometrium—ovarian cancer	0.000754	0.00758	CbGeAlD
Levonorgestrel—PGR—uterus—ovarian cancer	0.000695	0.00698	CbGeAlD
Levonorgestrel—SHBG—female reproductive system—ovarian cancer	0.000693	0.00697	CbGeAlD
Levonorgestrel—CYP19A1—endometrium—ovarian cancer	0.000678	0.00682	CbGeAlD
Levonorgestrel—AR—epithelium—ovarian cancer	0.00067	0.00673	CbGeAlD
Levonorgestrel—AR—uterine cervix—ovarian cancer	0.000664	0.00667	CbGeAlD
Levonorgestrel—ESR1—epithelium—ovarian cancer	0.000657	0.00661	CbGeAlD
Levonorgestrel—SHBG—bone marrow—ovarian cancer	0.000654	0.00658	CbGeAlD
Levonorgestrel—ESR1—uterine cervix—ovarian cancer	0.000652	0.00655	CbGeAlD
Levonorgestrel—AR—decidua—ovarian cancer	0.000633	0.00636	CbGeAlD
Levonorgestrel—SHBG—female gonad—ovarian cancer	0.000631	0.00634	CbGeAlD
Levonorgestrel—CYP19A1—gonad—ovarian cancer	0.000629	0.00632	CbGeAlD
Levonorgestrel—SHBG—vagina—ovarian cancer	0.000627	0.0063	CbGeAlD
Levonorgestrel—CYP19A1—uterus—ovarian cancer	0.000625	0.00628	CbGeAlD
Levonorgestrel—PGR—female reproductive system—ovarian cancer	0.000624	0.00628	CbGeAlD
Levonorgestrel—ESR1—decidua—ovarian cancer	0.000621	0.00624	CbGeAlD
Levonorgestrel—AR—endometrium—ovarian cancer	0.000601	0.00604	CbGeAlD
Levonorgestrel—ESR1—endometrium—ovarian cancer	0.00059	0.00592	CbGeAlD
Levonorgestrel—PGR—female gonad—ovarian cancer	0.000568	0.00571	CbGeAlD
Levonorgestrel—PGR—vagina—ovarian cancer	0.000565	0.00568	CbGeAlD
Levonorgestrel—CYP19A1—female reproductive system—ovarian cancer	0.000562	0.00565	CbGeAlD
Levonorgestrel—SHBG—testis—ovarian cancer	0.000559	0.00562	CbGeAlD
Levonorgestrel—AR—gonad—ovarian cancer	0.000557	0.0056	CbGeAlD
Levonorgestrel—AR—uterus—ovarian cancer	0.000553	0.00556	CbGeAlD
Levonorgestrel—ESR1—gonad—ovarian cancer	0.000547	0.0055	CbGeAlD
Levonorgestrel—ESR1—uterus—ovarian cancer	0.000543	0.00546	CbGeAlD
Levonorgestrel—CYP19A1—female gonad—ovarian cancer	0.000511	0.00514	CbGeAlD
Levonorgestrel—Ethynodiol—PGR—ovarian cancer	0.000506	0.0813	CrCbGaD
Levonorgestrel—PGR—testis—ovarian cancer	0.000504	0.00506	CbGeAlD
Levonorgestrel—AR—female reproductive system—ovarian cancer	0.000497	0.005	CbGeAlD
Levonorgestrel—ESR1—female reproductive system—ovarian cancer	0.000488	0.00491	CbGeAlD
Levonorgestrel—Norelgestromin—PGR—ovarian cancer	0.000477	0.0768	CrCbGaD
Levonorgestrel—Allylestrenol—PGR—ovarian cancer	0.000477	0.0768	CrCbGaD
Levonorgestrel—Desogestrel—PGR—ovarian cancer	0.00046	0.0739	CrCbGaD
Levonorgestrel—CYP19A1—testis—ovarian cancer	0.000453	0.00456	CbGeAlD
Levonorgestrel—AR—female gonad—ovarian cancer	0.000453	0.00455	CbGeAlD
Levonorgestrel—AR—vagina—ovarian cancer	0.00045	0.00452	CbGeAlD
Levonorgestrel—ESR1—female gonad—ovarian cancer	0.000444	0.00447	CbGeAlD
Levonorgestrel—ESR1—vagina—ovarian cancer	0.000442	0.00444	CbGeAlD
Levonorgestrel—Norgestimate—PGR—ovarian cancer	0.00043	0.0692	CrCbGaD
Levonorgestrel—AR—testis—ovarian cancer	0.000401	0.00403	CbGeAlD
Levonorgestrel—ESR1—testis—ovarian cancer	0.000394	0.00396	CbGeAlD
Levonorgestrel—Quinestrol—ESR1—ovarian cancer	0.000388	0.0624	CrCbGaD
Levonorgestrel—Etonogestrel—PGR—ovarian cancer	0.000372	0.0598	CrCbGaD
Levonorgestrel—PGR—lymph node—ovarian cancer	0.000365	0.00367	CbGeAlD
Levonorgestrel—CYP19A1—lymph node—ovarian cancer	0.000329	0.0033	CbGeAlD
Levonorgestrel—Ethynodiol—ESR1—ovarian cancer	0.000319	0.0513	CrCbGaD
Levonorgestrel—Allylestrenol—ESR1—ovarian cancer	0.000301	0.0485	CrCbGaD
Levonorgestrel—Mestranol—ESR1—ovarian cancer	0.000294	0.0473	CrCbGaD
Levonorgestrel—AR—lymph node—ovarian cancer	0.000291	0.00292	CbGeAlD
Levonorgestrel—Desogestrel—ESR1—ovarian cancer	0.00029	0.0467	CrCbGaD
Levonorgestrel—ESR1—lymph node—ovarian cancer	0.000286	0.00287	CbGeAlD
Levonorgestrel—CYP3A4—female reproductive system—ovarian cancer	0.000272	0.00274	CbGeAlD
Levonorgestrel—Norgestimate—ESR1—ovarian cancer	0.000271	0.0437	CrCbGaD
Levonorgestrel—Danazol—PGR—ovarian cancer	0.00024	0.0386	CrCbGaD
Levonorgestrel—Etonogestrel—ESR1—ovarian cancer	0.000235	0.0378	CrCbGaD
Levonorgestrel—Norethindrone—PGR—ovarian cancer	0.000213	0.0343	CrCbGaD
Levonorgestrel—Danazol—ESR1—ovarian cancer	0.000151	0.0243	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—ovarian cancer	0.00014	0.0225	CrCbGaD
Levonorgestrel—Progesterone—PGR—ovarian cancer	0.000124	0.02	CrCbGaD
Levonorgestrel—Progesterone—CYP1B1—ovarian cancer	0.000116	0.0187	CrCbGaD
Levonorgestrel—Anxiety—Paclitaxel—ovarian cancer	0.000116	0.00105	CcSEcCtD
Levonorgestrel—Malnutrition—Docetaxel—ovarian cancer	0.000116	0.00105	CcSEcCtD
Levonorgestrel—Erythema—Docetaxel—ovarian cancer	0.000116	0.00105	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000115	0.00105	CcSEcCtD
Levonorgestrel—Nausea—Topotecan—ovarian cancer	0.000115	0.00104	CcSEcCtD
Levonorgestrel—Discomfort—Paclitaxel—ovarian cancer	0.000115	0.00104	CcSEcCtD
Levonorgestrel—Mood swings—Doxorubicin—ovarian cancer	0.000114	0.00103	CcSEcCtD
Levonorgestrel—Diarrhoea—Vinorelbine—ovarian cancer	0.000113	0.00103	CcSEcCtD
Levonorgestrel—Abdominal distension—Epirubicin—ovarian cancer	0.000113	0.00102	CcSEcCtD
Levonorgestrel—Nausea—Melphalan—ovarian cancer	0.000113	0.00102	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—ovarian cancer	0.000112	0.00101	CcSEcCtD
Levonorgestrel—Asthma—Epirubicin—ovarian cancer	0.000112	0.00101	CcSEcCtD
Levonorgestrel—Back pain—Docetaxel—ovarian cancer	0.000112	0.00101	CcSEcCtD
Levonorgestrel—Oedema—Paclitaxel—ovarian cancer	0.000111	0.00101	CcSEcCtD
Levonorgestrel—Muscle spasms—Docetaxel—ovarian cancer	0.000111	0.00101	CcSEcCtD
Levonorgestrel—Infection—Paclitaxel—ovarian cancer	0.000111	0.001	CcSEcCtD
Levonorgestrel—Dry skin—Doxorubicin—ovarian cancer	0.00011	0.000995	CcSEcCtD
Levonorgestrel—Testosterone—CYP1B1—ovarian cancer	0.00011	0.0177	CrCbGaD
Levonorgestrel—Shock—Paclitaxel—ovarian cancer	0.00011	0.000993	CcSEcCtD
Levonorgestrel—Dizziness—Vinorelbine—ovarian cancer	0.000109	0.000992	CcSEcCtD
Levonorgestrel—Nervous system disorder—Paclitaxel—ovarian cancer	0.000109	0.000989	CcSEcCtD
Levonorgestrel—Breast disorder—Doxorubicin—ovarian cancer	0.000108	0.000981	CcSEcCtD
Levonorgestrel—Skin disorder—Paclitaxel—ovarian cancer	0.000108	0.00098	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—ovarian cancer	0.000108	0.000975	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000108	0.000975	CcSEcCtD
Levonorgestrel—Anaemia—Docetaxel—ovarian cancer	0.000107	0.000968	CcSEcCtD
Levonorgestrel—Anorexia—Paclitaxel—ovarian cancer	0.000106	0.000962	CcSEcCtD
Levonorgestrel—Vomiting—Vinorelbine—ovarian cancer	0.000105	0.000954	CcSEcCtD
Levonorgestrel—Dysuria—Epirubicin—ovarian cancer	0.000105	0.000948	CcSEcCtD
Levonorgestrel—Rash—Vinorelbine—ovarian cancer	0.000104	0.000946	CcSEcCtD
Levonorgestrel—Dermatitis—Vinorelbine—ovarian cancer	0.000104	0.000945	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—ovarian cancer	0.000104	0.000945	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000104	0.000943	CcSEcCtD
Levonorgestrel—Headache—Vinorelbine—ovarian cancer	0.000104	0.00094	CcSEcCtD
Levonorgestrel—Syncope—Docetaxel—ovarian cancer	0.000104	0.00094	CcSEcCtD
Levonorgestrel—Influenza—Doxorubicin—ovarian cancer	0.000104	0.000938	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—ovarian cancer	0.000104	0.000938	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—ovarian cancer	0.000103	0.000937	CcSEcCtD
Levonorgestrel—Palpitations—Docetaxel—ovarian cancer	0.000102	0.000926	CcSEcCtD
Levonorgestrel—Weight increased—Epirubicin—ovarian cancer	0.000102	0.000923	CcSEcCtD
Levonorgestrel—Loss of consciousness—Docetaxel—ovarian cancer	0.000102	0.000921	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000101	0.000919	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—ovarian cancer	0.000101	0.000918	CcSEcCtD
Levonorgestrel—Cough—Docetaxel—ovarian cancer	0.000101	0.000914	CcSEcCtD
Levonorgestrel—Insomnia—Paclitaxel—ovarian cancer	0.000101	0.000912	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—ovarian cancer	0.0001	0.00091	CcSEcCtD
Levonorgestrel—Hypertension—Docetaxel—ovarian cancer	9.98e-05	0.000905	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—ovarian cancer	9.98e-05	0.000904	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—ovarian cancer	9.98e-05	0.000904	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—ovarian cancer	9.96e-05	0.000902	CcSEcCtD
Levonorgestrel—Dyspnoea—Paclitaxel—ovarian cancer	9.93e-05	0.000899	CcSEcCtD
Levonorgestrel—Somnolence—Paclitaxel—ovarian cancer	9.9e-05	0.000897	CcSEcCtD
Levonorgestrel—Chest pain—Docetaxel—ovarian cancer	9.85e-05	0.000892	CcSEcCtD
Levonorgestrel—Myalgia—Docetaxel—ovarian cancer	9.85e-05	0.000892	CcSEcCtD
Levonorgestrel—Nausea—Vinorelbine—ovarian cancer	9.83e-05	0.000891	CcSEcCtD
Levonorgestrel—Dyspepsia—Paclitaxel—ovarian cancer	9.8e-05	0.000888	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	9.78e-05	0.000886	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—ovarian cancer	9.7e-05	0.000879	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—ovarian cancer	9.69e-05	0.000878	CcSEcCtD
Levonorgestrel—Decreased appetite—Paclitaxel—ovarian cancer	9.68e-05	0.000877	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—ovarian cancer	9.63e-05	0.000872	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Paclitaxel—ovarian cancer	9.61e-05	0.000871	CcSEcCtD
Levonorgestrel—Fatigue—Paclitaxel—ovarian cancer	9.6e-05	0.00087	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—ovarian cancer	9.57e-05	0.000867	CcSEcCtD
Levonorgestrel—Constipation—Paclitaxel—ovarian cancer	9.52e-05	0.000863	CcSEcCtD
Levonorgestrel—Pain—Paclitaxel—ovarian cancer	9.52e-05	0.000863	CcSEcCtD
Levonorgestrel—Oedema—Docetaxel—ovarian cancer	9.44e-05	0.000855	CcSEcCtD
Levonorgestrel—Weight increased—Doxorubicin—ovarian cancer	9.43e-05	0.000854	CcSEcCtD
Levonorgestrel—Infection—Docetaxel—ovarian cancer	9.38e-05	0.000849	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—ovarian cancer	9.37e-05	0.000849	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—ovarian cancer	9.36e-05	0.000848	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—ovarian cancer	9.29e-05	0.000842	CcSEcCtD
Levonorgestrel—Shock—Docetaxel—ovarian cancer	9.29e-05	0.000841	CcSEcCtD
Levonorgestrel—Nervous system disorder—Docetaxel—ovarian cancer	9.26e-05	0.000839	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—ovarian cancer	9.24e-05	0.000837	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—ovarian cancer	9.24e-05	0.000837	CcSEcCtD
Levonorgestrel—Skin disorder—Docetaxel—ovarian cancer	9.17e-05	0.000831	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.11e-05	0.000825	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—ovarian cancer	9.01e-05	0.000816	CcSEcCtD
Levonorgestrel—Anorexia—Docetaxel—ovarian cancer	9e-05	0.000815	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—ovarian cancer	8.98e-05	0.000814	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—ovarian cancer	8.98e-05	0.000813	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—ovarian cancer	8.96e-05	0.000812	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—ovarian cancer	8.92e-05	0.000808	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—ovarian cancer	8.89e-05	0.000806	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—ovarian cancer	8.85e-05	0.000802	CcSEcCtD
Levonorgestrel—Urticaria—Paclitaxel—ovarian cancer	8.85e-05	0.000801	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—ovarian cancer	8.81e-05	0.000798	CcSEcCtD
Levonorgestrel—Body temperature increased—Paclitaxel—ovarian cancer	8.8e-05	0.000797	CcSEcCtD
Levonorgestrel—Abdominal pain—Paclitaxel—ovarian cancer	8.8e-05	0.000797	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—ovarian cancer	8.78e-05	0.000796	CcSEcCtD
Levonorgestrel—Sinusitis—Doxorubicin—ovarian cancer	8.66e-05	0.000785	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—ovarian cancer	8.63e-05	0.000782	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.6e-05	0.000779	CcSEcCtD
Levonorgestrel—Insomnia—Docetaxel—ovarian cancer	8.54e-05	0.000773	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—ovarian cancer	8.47e-05	0.000768	CcSEcCtD
Levonorgestrel—Dyspnoea—Docetaxel—ovarian cancer	8.41e-05	0.000762	CcSEcCtD
Levonorgestrel—Somnolence—Docetaxel—ovarian cancer	8.39e-05	0.00076	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—ovarian cancer	8.37e-05	0.000759	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—ovarian cancer	8.33e-05	0.000755	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—ovarian cancer	8.32e-05	0.000753	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—ovarian cancer	8.31e-05	0.000753	CcSEcCtD
Levonorgestrel—Dyspepsia—Docetaxel—ovarian cancer	8.31e-05	0.000753	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—ovarian cancer	8.29e-05	0.000751	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—ovarian cancer	8.25e-05	0.000747	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—ovarian cancer	8.23e-05	0.000745	CcSEcCtD
Levonorgestrel—Decreased appetite—Docetaxel—ovarian cancer	8.2e-05	0.000743	CcSEcCtD
Levonorgestrel—Hypersensitivity—Paclitaxel—ovarian cancer	8.2e-05	0.000743	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—ovarian cancer	8.19e-05	0.000742	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.15e-05	0.000738	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—ovarian cancer	8.15e-05	0.000738	CcSEcCtD
Levonorgestrel—Fatigue—Docetaxel—ovarian cancer	8.14e-05	0.000737	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—ovarian cancer	8.13e-05	0.000736	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—ovarian cancer	8.09e-05	0.000733	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—ovarian cancer	8.08e-05	0.000732	CcSEcCtD
Levonorgestrel—Pain—Docetaxel—ovarian cancer	8.07e-05	0.000731	CcSEcCtD
Levonorgestrel—Constipation—Docetaxel—ovarian cancer	8.07e-05	0.000731	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—ovarian cancer	8e-05	0.000725	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—ovarian cancer	7.99e-05	0.000724	CcSEcCtD
Levonorgestrel—Asthenia—Paclitaxel—ovarian cancer	7.99e-05	0.000724	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—ovarian cancer	7.92e-05	0.000717	CcSEcCtD
Levonorgestrel—Pruritus—Paclitaxel—ovarian cancer	7.88e-05	0.000714	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—ovarian cancer	7.85e-05	0.000711	CcSEcCtD
Levonorgestrel—Progesterone—ESR1—ovarian cancer	7.85e-05	0.0126	CrCbGaD
Levonorgestrel—Erythema multiforme—Doxorubicin—ovarian cancer	7.84e-05	0.00071	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—ovarian cancer	7.8e-05	0.000707	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—ovarian cancer	7.8e-05	0.000707	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—ovarian cancer	7.75e-05	0.000702	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Docetaxel—ovarian cancer	7.72e-05	0.000699	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—ovarian cancer	7.69e-05	0.000697	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—ovarian cancer	7.69e-05	0.000696	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—ovarian cancer	7.65e-05	0.000693	CcSEcCtD
Levonorgestrel—Diarrhoea—Paclitaxel—ovarian cancer	7.62e-05	0.00069	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—ovarian cancer	7.58e-05	0.000686	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—ovarian cancer	7.54e-05	0.000684	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—ovarian cancer	7.5e-05	0.000679	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—ovarian cancer	7.49e-05	0.000678	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—ovarian cancer	7.47e-05	0.000677	CcSEcCtD
Levonorgestrel—Abdominal pain—Docetaxel—ovarian cancer	7.46e-05	0.000676	CcSEcCtD
Levonorgestrel—Body temperature increased—Docetaxel—ovarian cancer	7.46e-05	0.000676	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—ovarian cancer	7.41e-05	0.000671	CcSEcCtD
Levonorgestrel—Dizziness—Paclitaxel—ovarian cancer	7.36e-05	0.000667	CcSEcCtD
Levonorgestrel—Alopecia—Doxorubicin—ovarian cancer	7.33e-05	0.000664	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—ovarian cancer	7.26e-05	0.000658	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—ovarian cancer	7.22e-05	0.000654	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—ovarian cancer	7.22e-05	0.000654	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—ovarian cancer	7.21e-05	0.000653	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—ovarian cancer	7.11e-05	0.000644	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—ovarian cancer	7.08e-05	0.000642	CcSEcCtD
Levonorgestrel—Vomiting—Paclitaxel—ovarian cancer	7.08e-05	0.000641	CcSEcCtD
Levonorgestrel—Rash—Paclitaxel—ovarian cancer	7.02e-05	0.000636	CcSEcCtD
Levonorgestrel—Dermatitis—Paclitaxel—ovarian cancer	7.01e-05	0.000635	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—ovarian cancer	7.01e-05	0.000635	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—ovarian cancer	7.01e-05	0.000635	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—ovarian cancer	6.99e-05	0.000634	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—ovarian cancer	6.98e-05	0.000632	CcSEcCtD
Levonorgestrel—Headache—Paclitaxel—ovarian cancer	6.98e-05	0.000632	CcSEcCtD
Levonorgestrel—Hypersensitivity—Docetaxel—ovarian cancer	6.95e-05	0.00063	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—ovarian cancer	6.94e-05	0.000629	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—ovarian cancer	6.89e-05	0.000625	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—ovarian cancer	6.86e-05	0.000621	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—ovarian cancer	6.81e-05	0.000617	CcSEcCtD
Levonorgestrel—Asthenia—Docetaxel—ovarian cancer	6.77e-05	0.000613	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—ovarian cancer	6.73e-05	0.00061	CcSEcCtD
Levonorgestrel—Pruritus—Docetaxel—ovarian cancer	6.68e-05	0.000605	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—ovarian cancer	6.67e-05	0.000604	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—ovarian cancer	6.64e-05	0.000602	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—ovarian cancer	6.64e-05	0.000602	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—ovarian cancer	6.62e-05	0.0006	CcSEcCtD
Levonorgestrel—Nausea—Paclitaxel—ovarian cancer	6.61e-05	0.000599	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.59e-05	0.000597	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—ovarian cancer	6.56e-05	0.000594	CcSEcCtD
Levonorgestrel—Vertigo—Doxorubicin—ovarian cancer	6.48e-05	0.000587	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—ovarian cancer	6.47e-05	0.000586	CcSEcCtD
Levonorgestrel—Diarrhoea—Docetaxel—ovarian cancer	6.46e-05	0.000585	CcSEcCtD
Levonorgestrel—Palpitations—Doxorubicin—ovarian cancer	6.38e-05	0.000578	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—ovarian cancer	6.37e-05	0.000577	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—ovarian cancer	6.34e-05	0.000575	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—ovarian cancer	6.32e-05	0.000573	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—ovarian cancer	6.3e-05	0.000571	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—ovarian cancer	6.26e-05	0.000567	CcSEcCtD
Levonorgestrel—Nervous system disorder—Epirubicin—ovarian cancer	6.24e-05	0.000566	CcSEcCtD
Levonorgestrel—Dizziness—Docetaxel—ovarian cancer	6.24e-05	0.000565	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—ovarian cancer	6.23e-05	0.000565	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—ovarian cancer	6.18e-05	0.00056	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—ovarian cancer	6.15e-05	0.000558	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—ovarian cancer	6.14e-05	0.000557	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—ovarian cancer	6.14e-05	0.000557	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—ovarian cancer	6.12e-05	0.000555	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.1e-05	0.000553	CcSEcCtD
Levonorgestrel—Discomfort—Doxorubicin—ovarian cancer	6.07e-05	0.00055	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—ovarian cancer	6.07e-05	0.00055	CcSEcCtD
Levonorgestrel—Vomiting—Docetaxel—ovarian cancer	6e-05	0.000544	CcSEcCtD
Levonorgestrel—Rash—Docetaxel—ovarian cancer	5.95e-05	0.000539	CcSEcCtD
Levonorgestrel—Ethinyl Estradiol—ABCB1—ovarian cancer	5.95e-05	0.00957	CrCbGaD
Levonorgestrel—Dermatitis—Docetaxel—ovarian cancer	5.95e-05	0.000539	CcSEcCtD
Levonorgestrel—Headache—Docetaxel—ovarian cancer	5.91e-05	0.000536	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—ovarian cancer	5.89e-05	0.000534	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—ovarian cancer	5.85e-05	0.00053	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.8e-05	0.000525	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—ovarian cancer	5.8e-05	0.000525	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—ovarian cancer	5.78e-05	0.000523	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—ovarian cancer	5.76e-05	0.000522	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—ovarian cancer	5.72e-05	0.000518	CcSEcCtD
Levonorgestrel—Norethindrone—ABCB1—ovarian cancer	5.72e-05	0.0092	CrCbGaD
Levonorgestrel—Hyperhidrosis—Doxorubicin—ovarian cancer	5.69e-05	0.000516	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—ovarian cancer	5.68e-05	0.000514	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—ovarian cancer	5.66e-05	0.000513	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—ovarian cancer	5.61e-05	0.000509	CcSEcCtD
Levonorgestrel—Nausea—Docetaxel—ovarian cancer	5.61e-05	0.000508	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—ovarian cancer	5.6e-05	0.000508	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—ovarian cancer	5.53e-05	0.000501	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.5e-05	0.000498	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—ovarian cancer	5.49e-05	0.000497	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—ovarian cancer	5.44e-05	0.000493	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—ovarian cancer	5.44e-05	0.000493	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.37e-05	0.000486	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—ovarian cancer	5.33e-05	0.000483	CcSEcCtD
Levonorgestrel—Dyspnoea—Doxorubicin—ovarian cancer	5.25e-05	0.000476	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—ovarian cancer	5.24e-05	0.000474	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Epirubicin—ovarian cancer	5.21e-05	0.000472	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—ovarian cancer	5.18e-05	0.00047	CcSEcCtD
Levonorgestrel—Decreased appetite—Doxorubicin—ovarian cancer	5.12e-05	0.000464	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.09e-05	0.000461	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—ovarian cancer	5.08e-05	0.00046	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	5.07e-05	0.000739	CbGpPWpGaD
Levonorgestrel—Urticaria—Epirubicin—ovarian cancer	5.06e-05	0.000458	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—ovarian cancer	5.04e-05	0.000456	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—ovarian cancer	5.04e-05	0.000456	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—ovarian cancer	5.03e-05	0.000456	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—ovarian cancer	5.03e-05	0.000456	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PIK3CG—ovarian cancer	4.93e-05	0.000719	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—PIK3CA—ovarian cancer	4.92e-05	0.000718	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—DOK1—ovarian cancer	4.91e-05	0.000716	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NR5A1—ovarian cancer	4.9e-05	0.000715	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	4.9e-05	0.000714	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	4.83e-05	0.000704	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.82e-05	0.000436	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.81e-05	0.000701	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—ERBB2—ovarian cancer	4.8e-05	0.0007	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	4.77e-05	0.000695	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	4.77e-05	0.000695	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—YAP1—ovarian cancer	4.77e-05	0.000695	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL6—ovarian cancer	4.76e-05	0.000694	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—MTOR—ovarian cancer	4.74e-05	0.000691	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PIK3CB—ovarian cancer	4.74e-05	0.000691	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	4.72e-05	0.000688	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PARP1—ovarian cancer	4.72e-05	0.000688	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.72e-05	0.000687	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—ovarian cancer	4.71e-05	0.000686	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	4.7e-05	0.000686	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—AKT1—ovarian cancer	4.7e-05	0.000686	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—ovarian cancer	4.69e-05	0.000425	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—ovarian cancer	4.68e-05	0.000424	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—ovarian cancer	4.66e-05	0.000422	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—ovarian cancer	4.66e-05	0.000422	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—PPP1CC—ovarian cancer	4.62e-05	0.000673	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR1—ovarian cancer	4.61e-05	0.000673	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	4.6e-05	0.000671	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.59e-05	0.000669	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—ovarian cancer	4.57e-05	0.000414	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—ovarian cancer	4.56e-05	0.000664	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.55e-05	0.000663	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—ovarian cancer	4.5e-05	0.000408	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—AKT1—ovarian cancer	4.49e-05	0.000655	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—DLC1—ovarian cancer	4.47e-05	0.000652	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—CDKN1B—ovarian cancer	4.45e-05	0.000649	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.45e-05	0.000648	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—ovarian cancer	4.44e-05	0.000648	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.43e-05	0.000646	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	4.38e-05	0.000639	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—IL6—ovarian cancer	4.36e-05	0.000636	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—ovarian cancer	4.36e-05	0.000395	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	4.35e-05	0.000634	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	4.35e-05	0.000634	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Doxorubicin—ovarian cancer	4.34e-05	0.000393	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PIK3CD—ovarian cancer	4.33e-05	0.000632	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	4.27e-05	0.000622	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—ovarian cancer	4.23e-05	0.000383	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	4.23e-05	0.000616	CbGpPWpGaD
Levonorgestrel—Dizziness—Epirubicin—ovarian cancer	4.21e-05	0.000381	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—ovarian cancer	4.17e-05	0.000378	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	4.16e-05	0.000606	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—AKT1—ovarian cancer	4.15e-05	0.000606	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYTB—ovarian cancer	4.14e-05	0.000604	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	4.12e-05	0.0006	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	4.11e-05	0.000599	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PTEN—ovarian cancer	4.1e-05	0.000597	CbGpPWpGaD
Levonorgestrel—Hydrocortisone—ABCB1—ovarian cancer	4.09e-05	0.00658	CrCbGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.05e-05	0.00059	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—ovarian cancer	4.05e-05	0.000367	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—ovarian cancer	4.03e-05	0.000365	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—AKT1—ovarian cancer	4.02e-05	0.000586	CbGpPWpGaD
Levonorgestrel—Rash—Epirubicin—ovarian cancer	4.01e-05	0.000364	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—ovarian cancer	4.01e-05	0.000363	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	4e-05	0.000583	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	4e-05	0.000583	CbGpPWpGaD
Levonorgestrel—Headache—Epirubicin—ovarian cancer	3.99e-05	0.000361	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	3.91e-05	0.00057	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—ovarian cancer	3.9e-05	0.000353	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—PARP1—ovarian cancer	3.87e-05	0.000564	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	3.82e-05	0.000557	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.79e-05	0.000552	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—ovarian cancer	3.78e-05	0.000343	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PIK3CB—ovarian cancer	3.78e-05	0.000551	CbGpPWpGaD
Levonorgestrel—Vomiting—Doxorubicin—ovarian cancer	3.75e-05	0.000339	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	3.74e-05	0.000545	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	3.74e-05	0.000545	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	3.72e-05	0.000542	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—ovarian cancer	3.71e-05	0.000336	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—ovarian cancer	3.71e-05	0.000336	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.71e-05	0.00054	CbGpPWpGaD
Levonorgestrel—Headache—Doxorubicin—ovarian cancer	3.69e-05	0.000334	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.68e-05	0.000537	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—ovarian cancer	3.65e-05	0.000533	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—ovarian cancer	3.65e-05	0.000532	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BCL9—ovarian cancer	3.65e-05	0.000532	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.63e-05	0.00053	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—YAP1—ovarian cancer	3.63e-05	0.000529	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPP1CC—ovarian cancer	3.62e-05	0.000528	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—BRIP1—ovarian cancer	3.62e-05	0.000528	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.6e-05	0.000525	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.6e-05	0.000525	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.54e-05	0.000515	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	3.53e-05	0.000515	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—ESR1—ovarian cancer	3.52e-05	0.000513	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.5e-05	0.00051	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HDAC6—ovarian cancer	3.5e-05	0.00051	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—MAPK3—ovarian cancer	3.5e-05	0.00051	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—ovarian cancer	3.5e-05	0.000317	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	3.42e-05	0.000499	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.41e-05	0.000498	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.4e-05	0.000496	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	3.35e-05	0.000488	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	3.35e-05	0.000488	CbGpPWpGaD
Levonorgestrel—Progesterone—ABCB1—ovarian cancer	3.33e-05	0.00536	CrCbGaD
Levonorgestrel—ESR1—Signaling by ERBB4—MAPK1—ovarian cancer	3.33e-05	0.000486	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—ovarian cancer	3.33e-05	0.000485	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PTEN—ovarian cancer	3.26e-05	0.000476	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—IL6—ovarian cancer	3.25e-05	0.000474	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PGR—ovarian cancer	3.17e-05	0.000462	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	3.16e-05	0.000461	CbGpPWpGaD
Levonorgestrel—Testosterone—ABCB1—ovarian cancer	3.15e-05	0.00507	CrCbGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—ovarian cancer	3.15e-05	0.000459	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	3.14e-05	0.000458	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PPP2R1A—ovarian cancer	3.14e-05	0.000457	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.13e-05	0.000456	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—YAP1—ovarian cancer	3.1e-05	0.000452	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.08e-05	0.000449	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	3.08e-05	0.000449	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	3.08e-05	0.000449	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.04e-05	0.000443	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—XIAP—ovarian cancer	3.04e-05	0.000443	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.02e-05	0.000441	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SMARCA4—ovarian cancer	2.96e-05	0.000431	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PARP1—ovarian cancer	2.95e-05	0.00043	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.92e-05	0.000425	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PIK3CA—ovarian cancer	2.89e-05	0.000421	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EREG—ovarian cancer	2.89e-05	0.000421	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—DOK1—ovarian cancer	2.88e-05	0.00042	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.84e-05	0.000413	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	2.81e-05	0.00041	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—YAP1—ovarian cancer	2.8e-05	0.000408	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.77e-05	0.000404	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.77e-05	0.000404	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	2.71e-05	0.000395	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	2.67e-05	0.00039	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.65e-05	0.000387	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.64e-05	0.000385	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.62e-05	0.000382	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6—ovarian cancer	2.56e-05	0.000373	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.55e-05	0.000372	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PARP1—ovarian cancer	2.52e-05	0.000367	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PGR—ovarian cancer	2.44e-05	0.000356	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—YAP1—ovarian cancer	2.43e-05	0.000354	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.41e-05	0.000351	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.4e-05	0.00035	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—ovarian cancer	2.4e-05	0.00035	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPP2R1A—ovarian cancer	2.39e-05	0.000349	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.37e-05	0.000346	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	2.36e-05	0.000344	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.33e-05	0.00034	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PIK3CA—ovarian cancer	2.3e-05	0.000336	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PARP1—ovarian cancer	2.27e-05	0.000331	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR1—ovarian cancer	2.22e-05	0.000324	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.11e-05	0.000308	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HDAC6—ovarian cancer	2.05e-05	0.0003	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	2.04e-05	0.000297	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—FASN—ovarian cancer	1.98e-05	0.000289	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.97e-05	0.000287	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SLC5A5—ovarian cancer	1.95e-05	0.000284	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—ovarian cancer	1.88e-05	0.000274	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SLC2A1—ovarian cancer	1.88e-05	0.000274	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NME2—ovarian cancer	1.88e-05	0.000274	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.84e-05	0.000269	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPP2R1A—ovarian cancer	1.84e-05	0.000269	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—ovarian cancer	1.83e-05	0.000267	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—YAP1—ovarian cancer	1.82e-05	0.000265	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP1B1—ovarian cancer	1.8e-05	0.000263	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—XIAP—ovarian cancer	1.78e-05	0.00026	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	1.74e-05	0.000253	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EREG—ovarian cancer	1.69e-05	0.000247	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR1—ovarian cancer	1.69e-05	0.000247	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TERT—ovarian cancer	1.62e-05	0.000236	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	1.6e-05	0.000233	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.59e-05	0.000232	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PGR—ovarian cancer	1.59e-05	0.000232	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CAV1—ovarian cancer	1.5e-05	0.000219	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ABCB1—ovarian cancer	1.49e-05	0.000217	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PARP1—ovarian cancer	1.48e-05	0.000215	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMS—ovarian cancer	1.46e-05	0.000213	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—ovarian cancer	1.44e-05	0.000211	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6ST—ovarian cancer	1.42e-05	0.000207	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	1.41e-05	0.000205	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APC—ovarian cancer	1.37e-05	0.000199	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CG—ovarian cancer	1.37e-05	0.000199	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYTB—ovarian cancer	1.21e-05	0.000176	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CD—ovarian cancer	1.2e-05	0.000175	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	1.2e-05	0.000175	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MAPK3—ovarian cancer	1.19e-05	0.000173	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CAV1—ovarian cancer	1.18e-05	0.000171	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—ovarian cancer	1.16e-05	0.000168	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.12e-05	0.000164	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CG—ovarian cancer	1.07e-05	0.000156	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—ovarian cancer	1.06e-05	0.000155	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.06e-05	0.000154	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.06e-05	0.000154	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MTOR—ovarian cancer	1.05e-05	0.000153	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CB—ovarian cancer	1.05e-05	0.000153	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—ovarian cancer	1.01e-05	0.000147	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1B—ovarian cancer	9.82e-06	0.000143	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—ovarian cancer	9.62e-06	0.00014	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—ovarian cancer	9.61e-06	0.00014	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—ovarian cancer	9.51e-06	0.000139	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CD—ovarian cancer	9.41e-06	0.000137	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—ovarian cancer	9.37e-06	0.000137	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—ovarian cancer	9.28e-06	0.000135	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—ovarian cancer	9.09e-06	0.000133	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MAPK3—ovarian cancer	9.05e-06	0.000132	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—ovarian cancer	9.04e-06	0.000132	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—ovarian cancer	8.8e-06	0.000128	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CAV1—ovarian cancer	8.8e-06	0.000128	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6ST—ovarian cancer	8.34e-06	0.000122	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CB—ovarian cancer	8.2e-06	0.00012	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—ovarian cancer	8.17e-06	0.000119	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—ovarian cancer	8.09e-06	0.000118	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—ovarian cancer	8.07e-06	0.000118	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APC—ovarian cancer	8.01e-06	0.000117	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	8.01e-06	0.000117	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—ovarian cancer	8.01e-06	0.000117	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK3—ovarian cancer	7.73e-06	0.000113	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—ovarian cancer	7.51e-06	0.00011	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK1—ovarian cancer	7.35e-06	0.000107	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—ovarian cancer	7.35e-06	0.000107	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—YAP1—ovarian cancer	7.09e-06	0.000103	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—ovarian cancer	7.09e-06	0.000103	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	7.05e-06	0.000103	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MAPK3—ovarian cancer	6.97e-06	0.000102	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—ovarian cancer	6.94e-06	0.000101	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—ovarian cancer	6.78e-06	9.89e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—ovarian cancer	6.38e-06	9.3e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—ovarian cancer	6.22e-06	9.07e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—ovarian cancer	6.17e-06	9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MTOR—ovarian cancer	6.14e-06	8.95e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	6.14e-06	8.95e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—ovarian cancer	6.11e-06	8.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—ovarian cancer	5.9e-06	8.6e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—ovarian cancer	5.9e-06	8.6e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—FASN—ovarian cancer	5.78e-06	8.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	5.76e-06	8.4e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.68e-06	8.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—ovarian cancer	5.65e-06	8.24e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—ovarian cancer	5.65e-06	8.23e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—ovarian cancer	5.64e-06	8.22e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—ovarian cancer	5.5e-06	8.02e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.49e-06	8e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	5.44e-06	7.94e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—ovarian cancer	5.34e-06	7.78e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—ovarian cancer	5.31e-06	7.74e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.26e-06	7.67e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—ovarian cancer	5.21e-06	7.6e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—ovarian cancer	5e-06	7.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—ovarian cancer	4.79e-06	6.99e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—ovarian cancer	4.75e-06	6.92e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—ovarian cancer	4.73e-06	6.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—ovarian cancer	4.7e-06	6.86e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.67e-06	6.81e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK3—ovarian cancer	4.53e-06	6.61e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—ovarian cancer	4.41e-06	6.43e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.33e-06	6.32e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK1—ovarian cancer	4.31e-06	6.29e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—ovarian cancer	4.31e-06	6.29e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMS—ovarian cancer	4.26e-06	6.21e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—ovarian cancer	4.09e-06	5.96e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—ovarian cancer	4.07e-06	5.94e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	3.74e-06	5.46e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—ovarian cancer	3.62e-06	5.28e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—ovarian cancer	3.46e-06	5.05e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CAV1—ovarian cancer	3.43e-06	5e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—ovarian cancer	3.32e-06	4.83e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.12e-06	4.56e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—ovarian cancer	3.06e-06	4.46e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.75e-06	4e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.39e-06	3.49e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—ovarian cancer	2.07e-06	3.02e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.46e-06	2.13e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—ovarian cancer	1.19e-06	1.74e-05	CbGpPWpGaD
